Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the eighteen research firms that are currently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. The average 1 year target price among brokers that have issued a report on the stock in the last year is $131.8125.
RYTM has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rhythm Pharmaceuticals in a research note on Tuesday, April 21st. Bank of America decreased their price target on shares of Rhythm Pharmaceuticals from $145.00 to $139.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Citigroup decreased their price target on shares of Rhythm Pharmaceuticals from $136.00 to $131.00 and set a “buy” rating on the stock in a research note on Tuesday, March 17th. Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 price target on shares of Rhythm Pharmaceuticals in a research note on Tuesday, March 3rd. Finally, Canaccord Genuity Group raised their target price on shares of Rhythm Pharmaceuticals from $140.00 to $143.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th.
Get Our Latest Stock Report on Rhythm Pharmaceuticals
Rhythm Pharmaceuticals Trading Down 0.5%
Rhythm Pharmaceuticals (NASDAQ:RYTM – Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.03. The firm had revenue of $60.11 million for the quarter, compared to analyst estimates of $55.78 million. Rhythm Pharmaceuticals had a negative net margin of 93.33% and a negative return on equity of 203.25%. Rhythm Pharmaceuticals’s quarterly revenue was up 83.8% compared to the same quarter last year. During the same period last year, the company posted ($0.81) EPS. On average, sell-side analysts predict that Rhythm Pharmaceuticals will post -3.18 EPS for the current fiscal year.
Insiders Place Their Bets
In other Rhythm Pharmaceuticals news, CAO Christopher Paul German sold 5,614 shares of the firm’s stock in a transaction that occurred on Wednesday, March 4th. The shares were sold at an average price of $89.56, for a total value of $502,789.84. Following the transaction, the chief accounting officer directly owned 160 shares of the company’s stock, valued at $14,329.60. This trade represents a 97.23% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.90% of the stock is owned by company insiders.
Institutional Inflows and Outflows
Institutional investors have recently bought and sold shares of the business. EverSource Wealth Advisors LLC increased its holdings in shares of Rhythm Pharmaceuticals by 303.0% during the 4th quarter. EverSource Wealth Advisors LLC now owns 266 shares of the company’s stock worth $28,000 after buying an additional 200 shares during the last quarter. Smartleaf Asset Management LLC increased its holdings in shares of Rhythm Pharmaceuticals by 97.2% during the 3rd quarter. Smartleaf Asset Management LLC now owns 286 shares of the company’s stock worth $29,000 after buying an additional 141 shares during the last quarter. SBI Securities Co. Ltd. increased its holdings in shares of Rhythm Pharmaceuticals by 73.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 343 shares of the company’s stock worth $37,000 after buying an additional 145 shares during the last quarter. GAMMA Investing LLC increased its holdings in shares of Rhythm Pharmaceuticals by 48.6% during the 4th quarter. GAMMA Investing LLC now owns 361 shares of the company’s stock worth $39,000 after buying an additional 118 shares during the last quarter. Finally, Optiver Holding B.V. increased its holdings in shares of Rhythm Pharmaceuticals by 65.2% during the 3rd quarter. Optiver Holding B.V. now owns 365 shares of the company’s stock worth $37,000 after buying an additional 144 shares during the last quarter.
About Rhythm Pharmaceuticals
Rhythm Pharmaceuticals, Inc is a clinicalâstage biotechnology company dedicated to developing targeted therapies for rare genetic diseases of obesity and metabolic dysfunction. The company’s research focuses on the melanocortinâ4 receptor (MC4R) pathway, which plays a central role in regulating appetite, energy expenditure and body weight. Using proprietary peptide technology, Rhythm aims to provide precision treatments to patients with specific genetic variants that disrupt normal weight regulation.
The company’s lead investigational product, setmelanotide, is a selective MC4R agonist designed to restore signaling in patients with deficiencies in genes such as POMC, LEPR and PCSK1.
Read More
- Five stocks we like better than Rhythm Pharmaceuticals
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
